India

HOLD (no change)


Consensus ratings*: Buy 9	Hold 16 Sell 9
Current price:	Rs1,884
Target price:	Rs2,000
Previous target:	Rs1,645
Up/downside:	6.2%
InCred Research / Consensus:	18.2%
Reuters:	CL.MN
Bloomberg:	CLGT IN
Market cap:	US\$6,248m
	Rs512,312m
Average daily turnover:	US\$7.0m
	Rs574.0m
Current shares o/s:	272.0m
Free float: *Source: Bloomberg	49.0%

Key changes in this note

> Raise target price to Rs2,000.

> Raise FY24F/25F EPS by 4.5%/4.7%.

Introduce FY26F estimates.



Major shareholders	% held
Promoter	51.0
LIC	3.4
Blackrock	1.5



Anal	yst	(s)
------	-----	-----



Harsh SHAH T (91) 22 4161 1568 E harsh.shah@incredcapital.com Rohan KALLE T (91) 22 4161 1561 E rohan.kalle@incredcapital.com

Colgate Palmolive India

Improved execution in 1Q, but priced in

- Colgate-Palmolive India's 1Q domestic sales grew 12.3%, with toothpaste sales rising in high double digits. Volume growth rose due to CDC relaunch.
- Controlled overheads (flat yoy) and measured advertising expenses (13.7%/12.1% in 1QFY24/1HCY23) led to strong EBITDA margin expansion.
- Sales growth is competitive & execution has seen an improvement. However, the valuation at 41x/38x FY24F/25F EPS factors that in. Retain HOLD rating.

Competitive sales growth; sustaining volume growth is critical

Colgate-Palmolive India or CLGT's standalone net revenue in 1QFY24 was up 10.6% yoy. Domestic sales grew 12.3% yoy led by the toothpaste segment, which saw a high doubledigit growth led by relaunch of its flagship brand Colgate Dental Cream (CDC). We estimate the volume growth to be in the mid-single digit range. Management stated that there were early signs of a recovery in rural markets, and it expects sustained improvement. CLGT's domestic sales growth is competitive as Dabur India is expected to report a low doubledigit sales growth in its oral care segment (though Dabur India's oral care segment growth, on a 4-year CAGR at c.11% will be much higher than that of CLGT) while Hindustan Unilever or HUVR too called out double-digit growth in oral care. Pricing in the core portfolio and volume recovery, on a low base, should aid FY24F sales growth.

Premiumization agenda continues

Apart from the relaunch of its flagship brand, CLGT also launched its first-ever whitening pen, made via a tie-up with its dentist partners, which offers a new at-home teeth whitening experience. CLGT has been stepping up its premiumization agenda via its heightened focus on whitening as a play in the 'oral beauty' space and entering niche categories like therapeutics (launched PerioGard) & diabetics, and the renewed focus on nascent categories like body wash in the personal care segment under the Palmolive brand.

Improved execution

Gross margin/EBITDA margin expanded by 211bp/438bp yoy to 68.4%/31.6%, respectively. Despite the deferral of advertisement spending relating to relaunch of CDC to 1Q, 1QFY23/1HCY23 advertising expenses look quite reasonable at 13.7%/12.1%, respectively. We had estimated a higher spending on advertising. Other expenditure was also controlled and was flat yoy (15.9% of sales, down 180bp yoy) leading to a higher-than-estimated EBITDA margin. EBITDA/APAT grew 28%/34% yoy, respectively.

Maintain HOLD rating with a higher target price of Rs2,000

While the focus stays on premiumization, gaining volume market share at the bottom of the pyramid (core portfolio) is critical. Given the 1QFY24 results, we raise our sales/EPS estimates by 1.2%-4.7% for FY24F-25F, retaining our HOLD rating on the stock with a higher target price of Rs2,000 (40x Jun 2025F EPS, 5-year avg. P/E). Upside risk: Higher-than-expected sales growth. Downside risk: Lower-than-estimated EBITDA margin.


Financial Summary	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue (Rsm)	50,998	52,262	57,164	60,953	64,700
Operating EBITDA (Rsm)	15,659	15,470	17,639	18,909	20,161
Net Profit (Rsm)	10,783	10,583	12,449	13,406	14,357
Core EPS (Rs)	39.6	38.9	45.8	49.3	52.8
Core EPS Growth	4.1%	(1.9%)	17.6%	7.7%	7.1%
FD Core P/E (x)	47.51	48.41	41.15	38.22	35.68
DPS (Rs)	40.0	37.0	43.5	46.8	50.1
Dividend Yield	2.06%	2.06%	2.31%	2.49%	2.66%
EV/EBITDA (x)	32.29	32.57	28.75	26.78	25.07
P/FCFE (x)	125.22	40.78	60.82	37.84	35.23
Net Gearing	(38.7%)	(49.8%)	(28.9%)	(32.2%)	(35.7%)
P/BV (x)	29.54	29.85	28.81	27.76	26.72
ROE	74.4%	61.3%	71.2%	74.0%	76.3%
% Change In Core EPS Estimates			4.53%	4.68%	
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Improved execution in 1Q, but priced in

Y/E, Mar (Rs m)	1QFY23	4QFY23	1QFY24	YoY (%)	QoQ (%)
Revenue	11,968	13,506	13,237	10.6	-2.0
Expenditure	8,711	8,987	9,056	3.9	0.8
Cost of goods sold	4,031	4,475	4,179	3.7	-6.6
as % of sales	33.7	33.1	31.6		
Employee cost	937	898	958	2.2	6.6
as % of sales	7.8	6.7	7.2		
Ad spends	1,630	1,429	1,813	11.2	26.9
as % of sales	13.6	10.6	13.7		
Other expenditure	2,114	2,185	2,106	-0.4	-3.6
as % of sales	17.7	16.2	15.9		
EBITDA	3,257	4,519	4,181	28.4	-7.5
Depreciation	442	431	438	-0.9	1.5
EBIT	2,815	4,088	3,744	33.0	-8.4
Other income	115	204	150	29.7	-26.4
Interest	13	11	11		
РВТ	2,918	4,281	3,883	33.1	-9.3
Total tax	727	1,100	951	30.7	-13.5
Net profit (before extraordinary items)	2,190	3,181	2,932	33.9	-7.8
Extraordinary items	-24	-19	-195	NA	NA
Reported net profit	2,166	3,162	2,737	26.4	-13.5
Adjusted EPS	8.1	11.7	10.8	33.9	-7.8
Margins (%)				(bp)	(bp)
Gross margin	66.3	66.9	68.4	211	156
EBIDTA	27.2	33.5	31.6	438	-187
EBIT	23.5	30.3	28.3	476	-198
EBT	24.4	31.7	29.3	495	-236
Net profit	18.3	23.6	22.1	385	-140
Effective tax rate	24.9	25.7	24.5	-44	-120


Figure 2: Our rev	ised earr	nings estim	nates				
		FY24F			FY25F		FY26F
Y/E, Mar (Rs. m)	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduced
Revenue	56,460	57,164	1.2	60,210	60,953	1.2	64,700
EBITDA	16,900	17,639	4.4	18,133	18,909	4.3	20,161
EBITDA margin (%)	29.9	30.9	100 bp	30.1	31.0	90 bp	31.2
Net profit	11,910	12,449	4.5	12,806	13,406	4.7	14,357
EPS	43.8	45.8	4.5	47.1	49.3	4.7	52.8
				SOURCE:	INCRED RESE	ARCH, COMPA	NY REPORTS



InCred Equities

Personal Products | India Colgate Palmolive India | July 27, 2023

BY THE NUMBERS



Pro	fit 8	š Lo	SS

(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Net Revenues	50,998	52,262	57,164	60,953	64,700
Gross Profit	34,323	34,320	38,740	41,490	44,235
Operating EBITDA	15,659	15,470	17,639	18,909	20,161
Depreciation And Amortisation	(1,773)	(1,748)	(1,790)	(1,852)	(1,901)
Operating EBIT	13,886	13,722	15,849	17,057	18,259
Financial Income/(Expense)	179	462	506	555	603
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	25	25	26	27	29
Profit Before Tax (pre-El)	14,090	14,209	16,381	17,639	18,891
Exceptional Items					
Pre-tax Profit	14,090	14,209	16,381	17,639	18,891
Taxation	(3,307)	(3,625)	(3,931)	(4,233)	(4,534)
Exceptional Income - post-tax					
Profit After Tax	10,783	10,583	12,449	13,406	14,357
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	10,783	10,583	12,449	13,406	14,357
Recurring Net Profit	10,783	10,583	12,449	13,406	14,357
Fully Diluted Recurring Net Profit	10,783	10,583	12,449	13,406	14,357

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
EBITDA	15,659	15,470	17,639	18,909	20,161
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(8,044)	1,033	(4,315)	(219)	(215)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	263	536	577	622	672
Net Interest (Paid)/Received	(59)	(49)	(45)	(40)	(40)
Tax Paid	(3,307)	(3,625)	(3,931)	(4,233)	(4,534)
Cashflow From Operations	4,512	13,364	9,924	15,039	16,044
Сарех	(525)	(659)	(1,500)	(1,500)	(1,500)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments	186				
Other Investing Cashflow					
Cash Flow From Investing	(339)	(659)	(1,500)	(1,500)	(1,500)
Debt Raised/(repaid)	(81)	(141)			
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(10,572)	(10,575)	(11,827)	(12,736)	(13,639)
Preferred Dividends					
Other Financing Cashflow	5,292	(356)	(45)	(40)	(40)
Cash Flow From Financing	(5,361)	(11,072)	(11,872)	(12,776)	(13,679)
Total Cash Generated	(1,188)	1,634	(3,448)	764	864
Free Cashflow To Equity	4,091	12,565	8,424	13,539	14,544
Free Cashflow To Firm	4,232	12,755	8,469	13,579	14,584

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Personal Products | India Colgate Palmolive India | July 27, 2023

BY THE NUMBERS...cont'd

(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Cash And Equivalents	7,547	9,230	5,827	6,631	7,53
Total Debtors	2,247	1,574	1,915	2,042	2,168
Inventories	3,572	3,355	3,884	4,141	4,396
Total Other Current Assets	4,631	4,625	7,636	8,143	8,643
Total Current Assets	17,997	18,783	19,263	20,958	22,74
Fixed Assets	10,848	9,759	9,469	9,117	8,715
Total Investments					
Intangible Assets					
Total Other Non-Current Assets	173	288	288	288	288
Total Non-current Assets	11,021	10,047	9,757	9,405	9,004
Short-term Debt					
Current Portion of Long-Term Debt					
Total Creditors					
Other Current Liabilities	9,861	9,835	9,730	10,350	10,965
Total Current Liabilities	9,861	9,835	9,730	10,350	10,96
Total Long-term Debt					
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	831	690	690	690	69
Total Non-current Liabilities	831	690	690	690	69
Total Provisions	980	1,141	814	866	918
Total Liabilities	11,672	11,666	11,234	11,906	12,57
Shareholders Equity	17,347	17,164	17,786	18,457	19,17
Minority Interests					
Total Equity	17,347	17,164	17,786	18,457	19,17
Key Ratios					
Key Ratios	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26
Key Ratios Revenue Growth	Mar-22A 5.3%	Mar-23A 2.5%	Mar-24F 9.4%	Mar-25F 6.6%	
					6.1%
Revenue Growth	5.3%	2.5%	9.4%	6.6%	6.1% 6.6%
Revenue Growth Operating EBITDA Growth	5.3% 3.7%	2.5% (1.2%)	9.4% 14.0%	6.6% 7.2%	6.1% 6.6% 31.2%
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin	5.3% 3.7% 30.7%	2.5% (1.2%) 29.6%	9.4% 14.0% 30.9%	6.6% 7.2% 31.0%	6.1% 6.6% 31.2% 25.1
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs)	5.3% 3.7% 30.7% 24.69	2.5% (1.2%) 29.6% 31.40	9.4% 14.0% 30.9% 18.89	6.6% 7.2% 31.0% 21.84	6.1% 6.6% 31.2% 25.1 70.4%
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs)	5.3% 3.7% 30.7% 24.69 63.78	2.5% (1.2%) 29.6% 31.40 63.10	9.4% 14.0% 30.9% 18.89 65.39	6.6% 7.2% 31.0% 21.84 67.86	6.19 6.69 31.29 25.1 70.4 456.4
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover	5.3% 3.7% 30.7% 24.69 63.78 235.76	2.5% (1.2%) 29.6% 31.40 63.10 279.47	9.4% 14.0% 30.9% 18.89 65.39 352.20	6.6% 7.2% 31.0% 21.84 67.86 426.43	6.19 6.69 31.29 25.1 70.4 456.4 24.09
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate	5.3% 3.7% 30.7% 24.69 63.78 235.76 23.5%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0%	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio	5.3% 3.7% 30.7% 24.69 63.78 235.76 23.5% 98.0%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0%	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09 11.8
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09 11.8
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09 11.8 76.1
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25	6.19 6.69 31.29 25.1 70.4: 456.4: 24.09 95.09 11.8: 76.1: 137.89
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%)	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85 119.6%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45 140.5%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70 117.7%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25 127.5%	6.1% 6.6% 31.2% 25.1 70.4% 456.4% 24.0% 95.0% 11.8% 76.1% 76.1% 95.0% 1137.8% 96.4%
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%)	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85 75.85 119.6% 91.7%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45 140.5% 78.4%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70 117.7% 89.7%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25 127.5% 93.3%	Mar-26l 6.19 6.69 31.29 25.11 70.44 456.49 95.09 11.88 76.11 137.89 96.49 44.39
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%)	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85 75.85 119.6% 91.7%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45 140.5% 78.4%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70 117.7% 89.7%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25 127.5% 93.3%	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09 11.8 76.1 76.1 137.89 96.49
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) Return On Average Assets	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85 75.85 119.6% 91.7%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45 140.5% 78.4%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70 117.7% 89.7%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25 127.5% 93.3%	6.19 6.69 31.29 25.1 70.4 456.4 456.4 95.09 91.18 76.1 137.89 96.49 44.39
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) Return On Average Assets	5.3% 3.7% 30.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85 119.6% 91.7% 36.6%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45 140.5% 78.4% 35.0%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70 117.7% 89.7% 41.3%	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25 127.5% 93.3% 43.3%	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09 11.8 76.1 137.89 96.49 44.39
Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) Return On Average Assets	5.3% 3.7% 24.69 63.78 235.76 23.5% 98.0% 12.23 75.85 119.6% 91.7% 36.6%	2.5% (1.2%) 29.6% 31.40 63.10 279.47 25.5% 99.9% 13.34 70.45 140.5% 78.4% 35.0%	9.4% 14.0% 30.9% 18.89 65.39 352.20 24.0% 95.0% 11.14 71.70 117.7% 89.7% 41.3% Mar-24F	6.6% 7.2% 31.0% 21.84 67.86 426.43 24.0% 95.0% 11.85 75.25 127.5% 93.3% 43.3% Mar-25F	6.19 6.69 31.29 25.1 70.4 456.4 24.09 95.09 11.8 76.1 76.1 137.89 96.49

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000007793. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Personal Products | India Colgate Palmolive India | July 27, 2023

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report for date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
eceived any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from he subject company in the last twelve months	NO	NO
nanaged or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.